Who Really Needs Carotid Artery Surgery or Stenting? A Guide to Identifying High-Risk Patients with Asymptomatic Carotid Stenosis

Table of Contents

• Key Points
• Introduction: The Stroke Problem and the Carotid Artery Debate
• How This Research Was Conducted
• Risk Marker 1: Microemboli Detected by Transcranial Doppler (TCD)
• Risk Marker 2: Plaque Echolucency on Duplex Ultrasound
• Risk Marker 3: Progression of Stenosis Severity
• Risk Marker 4: Silent Embolic Infarcts on Brain CT or MRI
• Risk Marker 5: Reduced Cerebrovascular Reserve (CVR)
• Risk Marker 6: Size of the Juxtaluminal Hypoechoic Area
• Risk Marker 7: Intraplaque Haemorrhage Identified by MRI
• Risk Marker 8: Carotid Ulceration
• What the Guidelines Say: A Summary of Key Risk Factors
• Clinical Implications: What This Means for Patients
• Limitations of the Evidence
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Routine surgery for all asymptomatic carotid stenosis is outdated; individualized risk assessment with imaging is now recommended.
• TCD-detected microemboli (≥2 per hour) carry over a 1500% increased 1-year stroke risk in key studies.
• Combining TCD microemboli with echolucent plaque on ultrasound identifies a very high-risk group.
• Stenosis progression despite medical therapy roughly doubles the risk of future stroke or symptoms.
• MRI plaque features and silent brain infarcts on CT independently predict elevated stroke risk in asymptomatic patients.

Introduction: The Stroke Problem and the Carotid Artery Debate

Stroke is a devastating global health problem. In the United States alone, there are almost 800,000 strokes each year, causing about 140,000 deaths annually. Approximately 610,000 of these are first-ever strokes. In the United Kingdom, more than 100,000 strokes occur each year, and in 2015 alone, over 40,000 people died of stroke. The statistics are stark: stroke causes twice as many deaths per year in women than breast cancer, and twice as many deaths per year in men than prostate and testicular cancer combined.

Worldwide, stroke is the second most common cause of death, accounting for around 6.7 million deaths each year—that's one death every 5 seconds. About 85% of all strokes are ischaemic (caused by a blocked blood vessel), while 15% are haemorrhagic (caused by bleeding in the brain).

A substantial proportion of first-ever ischaemic strokes are caused by thromboemboli—blood clots that travel from a narrowed carotid artery in the neck up to the brain. The carotid arteries are the two main blood vessels on each side of the neck that deliver oxygen-rich blood to the brain. When these arteries become narrowed by cholesterol plaque—a condition called carotid stenosis—they can become a source of dangerous clots.

Back in the 1980s and 1990s, three landmark randomised controlled trials demonstrated that carotid endarterectomy (CEA)—a surgical procedure to remove the plaque from the carotid artery—conferred a 50% relative risk (RR) reduction in the 5-year stroke risk compared with best medical treatment (BMT) alone. As a result, offering CEA routinely to patients with asymptomatic carotid stenosis (ACS)—meaning carotid narrowing that hasn't yet caused any symptoms—was considered the treatment of choice.

However, in the early and mid-2000s, this approach began to change. Due to significant improvements in medical therapy—such as smoking cessation strategies, widespread use of statins, better blood pressure control, and antiplatelet therapy—the annual stroke rate among patients with ACS declined dramatically. It became clear that operating on every patient with asymptomatic carotid stenosis was no longer appropriate.

Yet, the opposite approach is equally problematic. Some experts argue that only best medical treatment should be offered to all patients with ACS, and that no one with asymptomatic stenosis should ever undergo prophylactic surgery. The authors of this review point out that this theory is not based on Level I Evidence—the highest tier of medical proof. Rather, it is an extrapolation from observational studies showing improved results with modern medical therapy.

The key question, then, is: Can we identify which patients with asymptomatic carotid stenosis are at high enough risk of stroke to justify a preventive intervention? This review article summarises the evidence for eight reliable predictors of future stroke risk in these patients.

How This Research Was Conducted

This is a comprehensive review article, not a single new clinical trial. The authors—three leading vascular surgery and stroke prevention specialists from the Royal Free Hospital in London, New York University Medical Center, and the Stroke Prevention & Atherosclerosis Research Centre at Western University in Canada—systematically examined and summarised the published scientific evidence on identifying high-risk patients with asymptomatic carotid stenosis.

They reviewed findings from numerous major studies, including large prospective observational studies (which follow patients forward in time), meta-analyses (which statistically combine results from multiple studies), and landmark clinical trials. The evidence base includes data from thousands of patients followed for periods ranging from approximately 1 to 8 years. The article also incorporates guideline recommendations from the 2017 European Society for Vascular Surgery (ESVS).

Risk Marker 1: Microemboli Detected by Transcranial Doppler (TCD)

Transcranial Doppler (TCD) is a non-invasive ultrasound technique that uses sound waves to measure blood flow in the brain's blood vessels through the skull. During a TCD examination, doctors can hear and visualise tiny particles—called microemboli—traveling through the bloodstream. These microemboli are essentially very small blood clots or plaque fragments that have broken loose from a carotid artery plaque and are heading toward the brain.

Imagine a tiny piece of plaque flaking off the artery wall and being carried by the blood toward the brain—that's a microembolus. When these are detected, they indicate an unstable plaque that may be at risk of causing a larger, symptomatic stroke.

The predictive value of TCD microemboli detection for identifying high-risk patients is well-established. The research group led by Dr. Spence was the first to report that patients with ACS who had more than 2 microemboli per hour on TCD had a >1500% increased risk of 1-year ipsilateral ischaemic stroke (meaning stroke on the same side of the brain as the narrowed carotid artery) compared with patients without TCD-detected microemboli. The actual numbers were stark: 15.6% vs 1.0% annual stroke risk (P<0.0001), a difference so large it is extremely unlikely to be due to chance.

In 2010, the same group reported further encouraging news. As a result of improvements in best medical treatment, there was a marked reduction in TCD-detected microemboli—from 12.6% before 2003 to 3.7% after 2003 (P<0.001)—and a corresponding reduction in cardiovascular events, from 17.6% to 5.2% (P<0.001), in 468 patients with ACS.

These results were verified in an independent, multicentre international study called the Asymptomatic Carotid Emboli Study (ACES), which followed 467 patients with ACS. As in the earlier study, patients had two 1-hour TCD recordings taken 1 week apart. Patients with one or more TCD emboli had a >550% higher risk of 1-year ipsilateral stroke compared with patients without emboli (HR: 5.57; 95% CI 1.61 to 19.32; P=0.007).

One earlier small study—a prospective observational cohort with only 202 patients—showed contradictory results, but it was underpowered (too small to detect a real difference). The authors note two likely reasons for its negative results: it accepted a single microembolus as a positive test (whereas the evidence supports needing at least two), and the test was repeated at 6-monthly intervals rather than more frequently.

A meta-analysis of five prospective studies (totalling 677 patients) confirmed that the presence of TCD-detected embolic signals is a significant predictor of ipsilateral stroke, with an odds ratio (OR) of 7.46 (95% CI 2.24 to 24.89; P=0.001). An odds ratio of 7.46 means that patients with microemboli have about seven and a half times the odds of having a stroke compared to those without—a very substantial increase in risk. The 2017 ESVS guidelines recommend considering carotid intervention based on the presence of TCD microemboli.

Risk Marker 2: Plaque Echolucency on Duplex Ultrasound

On a duplex ultrasound, doctors can examine the characteristics of the plaque inside the carotid artery. An important feature is echolucency—how "dark" or "black" the plaque appears on the ultrasound image. Early studies from the 1990s demonstrated that echolucent (dark-appearing) plaques correspond to a lipid-rich necrotic core (a soft, fatty, unstable centre) or intraplaque haemorrhage (bleeding inside the plaque)—features more commonly found in patients who have already had symptoms rather than in those with asymptomatic disease.

Multiple studies have evaluated whether plaque echolucency predicts future stroke risk in patients with ACS. The majority of studies independently reported a strong association between plaque echolucency and increased stroke risk. Here are the key studies:

• O'Holleran et al (1987): 293 patients, 46 months follow-up, relative risk (RR) of ipsilateral stroke 5.12 (95% CI 2.01 to 13.04)
• Polak et al (1998): 4,886 patients, 39.6 months follow-up, RR 1.96 (95% CI 1.25 to 2.90)
• Mathiesen et al (2001): 177 patients, 36 months follow-up, RR 3.85 (95% CI 0.46 to 32.28)
• Grønholdt et al (2001): 111 patients, 52.8 months follow-up, RR 0.87 (95% CI 0.34 to 2.23) — the only exception, from Denmark, suggesting echolucency was associated with stroke risk in symptomatic but not asymptomatic patients
• Nicolaides et al (2005): 1,092 patients, 37.1 months follow-up, RR 2.23 (95% CI 1.28 to 3.87)
• Topakian et al (2011): 435 patients, 21.8 months follow-up, RR 6.61 (95% CI 1.42 to 30.75)
• Silvestrini et al (2013): 621 patients, median 27 months follow-up, RR 2.37 (95% CI 1.14 to 4.92)
• Huibers et al (2016): 814 patients, 60 months follow-up, RR 2.52 (95% CI 1.20 to 5.25)

A recent meta-analysis pooling data from 7,557 patients with a mean follow-up of 37.2 months demonstrated a positive association between plaque echolucency and the risk of future ipsilateral stroke, with a relative risk of 2.31 (95% CI 1.58 to 3.39; P<0.001). Of the total study sample, 1,741 patients (23.0%) had a positive ultrasound test for echolucency. During follow-up, 100 ipsilateral strokes occurred in the echolucent-positive group, while 141 occurred in the echolucency-negative group—a cumulative incidence of ipsilateral stroke of 5.7% vs 2.4%, respectively.

For patients with ≥50% carotid stenosis, the stroke risk was even higher (RR: 2.61; 95% CI 1.47 to 4.63; P=0.001). This association was verified in an independent meta-analysis as well.

Perhaps most importantly, the predictive value of echolucent plaque morphology increases even further when combined with TCD-detected emboli. In the ACES study, carotid plaque echolucency alone was associated with a >600% increased risk of ipsilateral stroke (HR: 6.43; 95% CI 1.36 to 30.44; P=0.019). But the combination of plaque echolucency with TCD-detected emboli was associated with a >1000% increased risk of ipsilateral stroke (HR: 10.61; 95% CI 2.98 to 37.82; P=0.0003). In other words, these two markers together signal a very dangerous plaque.

Risk Marker 3: Progression of Stenosis Severity

If a patient's carotid stenosis is getting more severe on successive ultrasound examinations despite receiving best medical treatment, that is not a good sign. The authors note that up to half of patients with ACS may have what is called "resistant atherosclerosis"—disease that continues to progress despite appropriate medical therapy.

The largest prospective study of patients with ACS undergoing medical intervention alone—the Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) study—demonstrated clearly that progression of stenosis severity predicts future stroke. The 8-year cumulative ipsilateral ischaemic stroke rate was:

• 0% in patients with regression (improvement) of stenosis
• 9% if the stenosis was unchanged
• 16% if there was progression of stenosis

Breaking this down further, among patients with unchanged stenosis, the 8-year cumulative ipsilateral cerebral ischaemic stroke rates for patients with baseline stenosis of 50%–69%, 70%–89%, and 90%–99% were 4%, 8%, and 13%, respectively. In contrast, in the presence of progression, the stroke rates jumped to 8%, 15%, and 25% respectively—showing that progression magnifies the risk at every level of stenosis severity.

An independent study from Boston, Massachusetts, verified these findings. This study followed 794 patients (900 carotid arteries) with moderate (50%–69%) ACS for a mean of 3.6 years (range: 0.3 to 6.7 years). Stenosis progression occurred in 262 of 900 (29.1%) carotid arteries despite best medical treatment, and 36 (13.7%) of these patients developed symptoms. The symptomatic conversion rate in patients with progression was considerably higher than in those without progression: 13.7% vs 8.5%, respectively (P=0.02). The researchers concluded that medical treatment failed to prevent carotid disease progression or the development of symptoms in a significant proportion of patients.

An earlier study of 1,065 patients with ACS followed with carotid ultrasound also confirmed these findings. During the initial study period (median 7.5 months), progression of carotid lesions was demonstrated in 93 of 1,065 patients (9%). During a median follow-up of 3.2 years, 495 major adverse cardiovascular events (a composite including heart attack, coronary interventions, bypass surgery, stroke, peripheral vascular procedures, amputation due to critical limb ischaemia, and all-cause death) were recorded in 421 patients (40%).

Patients with progressive ACS had a 200% higher risk of composite major adverse cardiovascular events compared with patients with non-progressive disease (adjusted HR: 2.01; 95% CI 1.48 to 2.67; P<0.001). This included:

• A >200% higher risk of myocardial infarction (heart attack) (HR: 2.38; 95% CI 1.07 to 5.35; P=0.044)
• A 200% higher risk for stroke (adjusted HR: 2.0; 95% CI 1.02 to 4.11; P=0.035)
• A 175% higher risk for cardiovascular death (adjusted HR: 1.75; 95% CI 1.03 to 2.97; P=0.039)

One particularly important insight from this body of research is that total plaque burden may be a better predictor of cardiovascular outcomes than traditional measurements. A study from Canada compared progression and regression of three measurements—carotid intima-media thickness (cIMT), total plaque area, and total plaque volume—as predictors of cardiovascular outcomes in 349 patients attending stroke prevention clinics. After a median follow-up of 3.17 years, there were 50 first events: 20 vascular deaths, 11 strokes, 13 transient ischaemic attacks (TIAs, or "mini-strokes"), and 6 heart attacks.

The results were striking:

• Progression of total plaque volume predicted stroke, death or TIA (P=0.001); stroke, death or heart attack (P=0.008); and stroke, death, TIA, or heart attack (P=0.001).
• Progression of total plaque area only weakly predicted stroke, TIA, or death (P=0.097), and did not predict stroke, death, or heart attack (P=0.59).
• Change in cIMT did not predict stroke, death, or heart attack (P=0.13).

The study concluded that measurement of total plaque volume is a superior predictor of cardiovascular events compared with either total plaque area or cIMT. In fact, in patients with ACS, plaque burden—not percent stenosis—predicted the risk of stroke. The High Risk Plaque BioImage study also found that plaque burden was strongly correlated with coronary calcium (a measure of heart disease burden) while IMT was not, and plaque burden was as predictive of events as coronary calcium.

Risk Marker 4: Silent Embolic Infarcts on Brain CT or MRI

Sometimes, tiny emboli (clots) break off from a carotid plaque and travel to the brain, causing small areas of brain damage that are too small to produce noticeable symptoms. These are called silent embolic infarcts—"silent" because the patient doesn't experience any symptoms, but the damage is visible on brain imaging scans such as CT (computed tomography) or MRI (magnetic resonance imaging).

Both the Cardiovascular Health Study and the Rotterdam Scan Study demonstrated that the presence of silent embolic infarcts on brain CT or MRI is associated with an increased risk of stroke in the general population. Two further studies—the ACSRS study and an independent study from Japan—showed that silent embolic infarcts are an independent predictor of stroke in patients with asymptomatic carotid stenosis.

In the ACSRS study, patients with 60%–99% ACS who had silent embolic infarcts on brain CT scans had a 300% higher risk of future ipsilateral stroke compared with patients without silent infarcts. The annual stroke rate was 3.6% vs 1.0%, respectively (HR: 3.0; 95% CI 1.46 to 6.29; P=0.002). This means that a silent infarct on a brain scan is essentially a warning sign that the carotid plaque is actively shedding material into the brain.

However, the authors note a limitation: brain CT scans may miss up to 40% of brain infarcts in patients with ACS. MRI is far more sensitive for detecting these small silent strokes.

Risk Marker 5: Reduced Cerebrovascular Reserve (CVR)

The brain has a remarkable ability to protect itself. When the carotid artery becomes narrowed, the pressure of blood flowing to the brain decreases. In response, the tiny blood vessels in the brain (cerebral arterioles) dilate—widen—to their maximum to maintain adequate blood flow. This protective mechanism is called cerebrovascular reserve (CVR), and doctors can measure it.

Normal CVR values range from as low as 15% up to 40%. Values below 10% suggest impaired CVR, meaning the brain's blood vessels are already maximally dilated and cannot compensate further if blood pressure drops.

Several studies have demonstrated that impairment in CVR is associated with the development of stroke in patients with ACS:

• Gur et al (1996): 44 patients, 21 with impaired CVR, 24 months follow-up, odds ratio (OR) 22.50
• Silvestrini et al (2000): 94 patients, 40 with impaired CVR, 28.5 months follow-up, OR 3.72 (95% CI 1.05 to 14.85)
• Markus and Cullinane (2001): 107 patients, 21.7 months follow-up, OR 14.4 (95% CI 2.63 to 78.74)
• Kimiagar et al (2010): 35 patients, 21 with impaired CVR, 48 months follow-up, OR 6.50 (95% CI 0.65 to 315.02)
• King et al (2011): 106 patients, 32 with impaired CVR, 22.7 months follow-up, OR 3.62 (95% CI 0.61 to 21.74)

A meta-analysis combining 13 studies with 991 patients and a mean follow-up of 32.7 months demonstrated an almost 400% higher stroke risk in asymptomatic patients with impaired cerebral blood flow (random effects OR: 3.96; 95% CI 2.60 to 6.04). Although the authors acknowledge limitations—including that investigators were not always blinded to CVR results and definitions of end-points varied between studies—they concluded that the association between CVR impairment and risk of stroke/TIA is robust. Reduced CVR may therefore identify patients with ACS who are at high risk for stroke.

Risk Marker 6: Size of the Juxtaluminal Hypoechoic Area

In unstable, symptom-causing plaques, the necrotic core (the soft, fatty centre of the plaque) is twice as close to the blood vessel lumen compared with asymptomatic carotid plaques. This proximity matters because a plaque component that is closer to the surface is more likely to rupture and release debris into the bloodstream.

Cross-sectional studies using ultrasound have demonstrated an association between the juxtaluminal hypoechoic (black) area—the dark-appearing region of the plaque directly adjacent to the blood flow channel—and the presence of neurological symptoms. The ACSRS study formally tested whether the presence and size of this juxtaluminal hypoechoic area, in the absence of a visible echogenic (bright) cap, predicts future ipsilateral ischaemic stroke in patients with ACS.

The results showed a powerful "dose-response" relationship. The 5-year ipsilateral cerebral or retinal ischaemic event rate was:

• 3% in patients with a juxtaluminal hypoechoic area smaller than 4 mm²
• 21% in patients with an area between 4 and 8 mm²
• 36% in patients with an area between 8 and 10 mm²
• 43% in patients with a juxtaluminal black area larger than 10 mm²

The average annual stroke rates were 0.6%, 4.2%, 7.2%, and 8.6%, respectively—a dramatic stepwise increase in risk as the dark area grows. This supports the theory that the size of the juxtaluminal hypoechoic area is a reliable predictor of future ipsilateral ischaemic stroke.

Risk Marker 7: Intraplaque Haemorrhage Identified by MRI

Magnetic resonance imaging (MRI) can look inside the carotid plaque itself and identify its specific components with remarkable detail. Three plaque features have been studied as potential predictors of stroke:

1. Intraplaque haemorrhage (IPH)—bleeding inside the plaque
2. Lipid-rich necrotic core (LRNC)—a soft, fatty, unstable core
3. Thinning or rupture of the fibrous cap (TRFC)—weakening of the protective covering of the plaque

Several studies have evaluated whether MRI assessment of these plaque components can predict stroke in patients with ACS:

• Takaya et al (2006): 154 patients, 38.2 months follow-up, IPH hazard ratio (HR) 5.2 (95% CI 1.6 to 7.3)
• Singh et al (2009): 98 patients, 24.9 months follow-up, IPH HR 2.48 to 4.71
• Sadat et al (2010): 61 patients, 16.9 months follow-up, IPH HR 1.27 to 26.77; TRFC HR 7.39 (95% CI 1.61 to 33.82); LRNC HR 1.75 (95% CI 0.55 to 5.54)
• Mono et al (2012): 65 patients, 18.9 months follow-up, IPH HR 0.03; TRFC HR 1.103 (95% CI 0.11 to 10.70); LRNC HR 7.2 (95% CI 1.12 to 46.28)
• Kwee et al (2013): 126 patients, 12.0 months follow-up, IPH HR 3.5 (95% CI 1.06 to 11.96); TRFC HR 5.8 (95% CI 1.91 to 17.32); LRNC HR 3.2 (95% CI 1.08 to 9.50)
• Hosseini et al (2013): 179 patients, 17.5 months follow-up, IPH HR 12 (95% CI 4.8 to 30.1)

The majority of these studies showed that carotid plaques with intraplaque haemorrhage, lipid-rich necrotic core, or thinning/rupture of the fibrous cap are significantly more likely to result in ipsilateral ischaemic events, with this increased risk present across a wide range of stenosis severity.

A meta-analysis combining 9 studies with 779 patients verified these findings. The hazard ratios for intraplaque haemorrhage, lipid-rich necrotic core, and thinning/rupture of the fibrous cap as predictors of subsequent stroke or TIA were 4.59 (95% CI 2.91–7.24), 3.00 (95% CI 1.51–5.95), and 5.93 (95% CI 2.65–13.20), respectively. This meta-analysis concluded that MRI characterisation of these specific plaque elements can provide additional measures of stroke risk not provided by simple measurement of luminal stenosis alone.

Risk Marker 8: Carotid Ulceration

Sometimes the surface of a carotid plaque develops an actual crater or ulceration—a break in the inner lining of the artery. Researchers have studied whether the volume of these ulcerations predicts risk. In one study, the total ulcer volume (TUV) was computed from tracing ulcer contours on cross-sectional ultrasound images, with each slice having a thickness of 1 mm.

The research demonstrated that patients with a total ulcer volume of ≥5.00 mm³ had significantly worse outcomes during follow-up compared with those with no ulcerations or smaller ulcers. The Kaplan–Meier survival analysis (a statistical method that tracks how many people reach a given endpoint over time) for participants with TUV ≥5.00 mm³ versus those with no ulcerations or TUV <5 mm³ showed a statistically significant difference (log-rank P=0.009) for the combined endpoint of stroke, TIA, or cardiovascular death.

Indeed, the 2017 European Society for Vascular Surgery guidelines list a prior contralateral stroke or TIA (a stroke or mini-stroke on the opposite side of the brain) as a clinical feature associated with increased risk of late stroke, with a hazard ratio of 3.0 (95% CI 1.9 to 4.73; P=0.0001)—suggesting that a history of cerebrovascular events anywhere in the brain may signal a generally more vulnerable vascular system.

What the Guidelines Say: A Summary of Key Risk Factors

The 2017 European Society for Vascular Surgery (ESVS) carotid guidelines consolidated the evidence into a clear table of clinical and imaging features associated with an increased risk of late stroke in patients with 50%–99% asymptomatic carotid stenosis treated medically. Here are the key risk markers and their associated risk increases:

• Spontaneous embolisation on TCD: OR 7.46 (95% CI 2.24 to 24.89); P=0.001
• Plaque echolucency on duplex ultrasound (vs echogenic): OR 2.61 (95% CI 1.47 to 4.63); P=0.001
• Spontaneous embolisation on TCD + uniformly or predominantly echolucent plaque (70%–99% stenoses): OR 10.61 (95% CI 2.98 to 37.82); P=0.0003
• Stenosis progression (50%–99% stenoses): OR 1.92 (95% CI 1.14 to 3.25); P=0.05
• Stenosis progression (70%–99% stenoses): OR 4.7 (95% CI 2.3 to 9.6)
• Silent infarction on CT (60%–99% stenoses): OR 3.0 (95% CI 1.46 to 6.29); P=0.002
• Impaired cerebrovascular reserve (70%–99% stenoses): OR 6.14 (95% CI 2.77 to 4.95); P<0.01
• Juxtaluminal black area on computerised plaque analysis (comparing areas <4 mm², 4–8 mm², 8–10 mm², >10 mm²): trend P<0.001
• Intraplaque haemorrhage on MRI: OR 3.66 (95% CI 2.77 to 4.95); P<0.01
• Contralateral stroke/TIA: OR 3.0 (95% CI 1.9 to 4.73); P=0.0001

Clinical Implications: What This Means for Patients

This body of evidence fundamentally changes how doctors should think about asymptomatic carotid stenosis. Rather than applying a "one-size-fits-all" approach—either operating on everyone or no one—modern practice calls for a personalised risk assessment.

All patients with ACS should receive best medical treatment, which includes statins to lower cholesterol, antiplatelet therapy, blood pressure control, smoking cessation, and diabetes management. But for patients who display one or more high-risk features described above, the risk of stroke may be high enough (often exceeding 2–3% per year, and sometimes much higher) that a preventive carotid intervention—either carotid endarterectomy (the surgical removal of plaque) or carotid artery stenting (inserting a mesh tube to hold the artery open)—is justified.

From the available evidence, the authors estimate that approximately 10%–15% of patients with asymptomatic stenosis might benefit from intervention. In 2005, Spence and colleagues reported that in the period from 2000 to 2005, 10% of patients with ACS had two or more microemboli on TCD—a straightforward way to identify a substantial proportion of these high-risk individuals.

It's important to understand what these statistics mean in real terms. A patient with TCD-detected microemboli and an echolucent plaque faces a risk of ipsilateral stroke that is more than ten times higher than a patient without these features. For such patients, the potential benefit of surgery is substantial—far exceeding the risks of the procedure itself, which in experienced centres is around 1–3% for perioperative stroke or death. On the other hand, for low-risk patients with stable, bright (echogenic) plaques, no microemboli, and no evidence of progression, yearly stroke risk may be under 1%, which is lower than the risk of surgery—and so medical management alone is clearly the right choice.

The authors emphasise that TCD embolus detection is currently the best validated method for identifying high-risk patients, and that combining multiple risk markers (such as TCD emboli with plaque echolucency) dramatically increases predictive power.

Limitations of the Evidence

As with any medical research, the studies underlying these recommendations have limitations. The authors note several:

• Conflicting results in some early studies: One early TCD study with only 202 patients found no significant association, though it was underpowered and used different criteria for a "positive" test.
• Blinding issues in CVR studies: In the majority of studies of cerebrovascular reserve, investigators were not blinded to the CVR results, which could potentially bias outcome assessment.
• Variations in study design: Definitions of study endpoints (stroke vs TIA) and definitions of "asymptomatic" versus "symptomatic" disease varied between studies.
• CT scan limitations: Brain CT may miss up to 40% of brain infarcts in patients with ACS, potentially underestimating the prevalence of silent infarcts when CT is used alone.
• Blinding not always reported in MRI studies: Some MRI studies described blinding of MRI results to researchers assessing ischaemic outcomes, while others did not report such blinding.
• Evolving medical therapy: The natural history of asymptomatic carotid stenosis continues to improve as medical therapy advances, and the authors note that the ongoing trials comparing stenting or endarterectomy with best medical therapy will clarify the picture further.

Recommendations for Patients

If you or a loved one has been diagnosed with asymptomatic carotid stenosis (a carotid narrowing that hasn't caused a stroke or mini-stroke), here are some practical takeaways from this research:

1. Don't assume no treatment is needed: While it's true that aggressive medical therapy has dramatically reduced stroke rates, the risk is not zero—and about 10–15% of patients with ACS face a much higher risk than the rest. Write down your exact degree of stenosis (e.g., 70%) and discuss it with a specialist.
2. Ask about TCD embolus detection: This non-invasive ultrasound test, which takes about an hour, checks for tiny particles traveling to the brain. Two or more microemboli per hour marks a >1500% increase in 1-year stroke risk—this is the single best-validated predictor.
3. Ask about plaque characterisation: Not all plaques are equal. If your plaque appears dark and "echolucent" on ultrasound, or

   Frequently Asked Questions

   I have asymptomatic carotid stenosis. Do I need surgery or stenting?

   Not automatically. Modern medical therapy—statins, blood pressure control, antiplatelet drugs, and lifestyle changes—is effective for many patients. However, about 10–15% of people with asymptomatic stenosis have a high enough stroke risk to benefit from preventive intervention. Doctors now use imaging tests to identify these high-risk individuals and personalize treatment decisions.

   My ultrasound says my plaque is 'echolucent'. What does that mean?

   Echolucent means the plaque appears dark on an ultrasound, suggesting a soft, fatty, unstable center. In pooled data from over 7,500 patients, echolucent plaques were associated with about a 2.3 times higher risk of future stroke compared with brighter plaques. When combined with microemboli detected on TCD, the risk is more than ten times higher.

   If my carotid narrowing is getting worse despite medication, is my risk higher?

   Yes. In the largest study of medically treated asymptomatic carotid stenosis, the 8-year stroke rate was 16% if stenosis progressed, versus 9% if it stayed unchanged and 0% if it regressed. An independent study found that progression roughly doubled the risk of symptoms. Worsening stenosis signals resistant atherosclerosis that may require more than just medical therapy.

   What are 'silent' brain infarcts and do they increase stroke risk?

   Silent embolic infarcts are tiny areas of brain damage caused by clots from a carotid plaque, but they are too small to cause noticeable symptoms. They show up on CT or MRI scans. In the ACSRS study, patients with a silent infarct on CT had a 3 times higher annual risk of future stroke compared to those without one.

   Can an MRI of my carotid plaque help predict stroke risk?

   Yes. MRI can detect specific plaque features such as intraplaque haemorrhage (bleeding inside the plaque), a lipid-rich necrotic core, and thinning or rupture of the fibrous cap. A meta-analysis found these features increased stroke risk by roughly 3- to 6-fold. This information can add to the risk assessment beyond just measuring how narrow the artery is.

   What does 'reduced cerebrovascular reserve' mean and is it dangerous?

   Cerebrovascular reserve is the brain's ability to widen its small blood vessels to maintain blood flow when a carotid artery is narrowed. When this reserve is impaired (below about 10%), the brain cannot compensate further. In a meta-analysis of 13 studies, asymptomatic patients with impaired reserve had nearly a 4 times higher risk of stroke.

   When should I seek a second opinion about surgery or stenting for asymptomatic carotid stenosis?

   Many patients with asymptomatic carotid stenosis do not benefit from surgery or stenting; only about 10–15% are high-risk enough to justify it. Intervention is generally considered when risk markers are present, such as two or more microemboli per hour on transcranial Doppler, echolucent plaque, stenosis progression, silent brain infarcts, or impaired cerebrovascular reserve. A second opinion can review your imaging and ultrasound findings to determine whether you have these high-risk features or whether medical treatment alone is the safer choice. Diagnostic Detectives Network provides independent expert second opinions.